65,437 trials
Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) of Gemtuzumab Ozogamicin (GO) When Added to GCLAM (Phase 1) — NA; NA Participants
Peripheral Arterial Disease
Primary: Technical Success — 144 lesion
Covid-19 · Deconditioning
Primary: Adherence (Primary Feasibility/Safety Outcome) — 93 % of participants meeting adherence
COVID-19
Primary: Improvement in Oxygenation — 25.7; 29.7 ratio
Atopic Dermatitis
Primary: Double-blind Treatment Period: Percent Change in Eczema Area and Severity Index (EASI) Score — -58.68; -57.18; -48.41 Percent change — p==0.1198
Olfactory Disorder
Primary: Pre- and Post-intervention Difference in Functional Connectivity Before and After Smell Training. — 5 Regions of interest
COVID-19
Primary: Composite of All-cause Mortality, Need for Mechanical Ventilation, or Need for Mechanical Circulatory Support (MCS) — 9; 6 Participants
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL)
Primary: Percentage of Participants Achieving Low Tumor Burden Status With Induction of Obinutuzumab or Obinutuzumab Plus Bendamustine (Debulking Period) — 81.4; 83.9; 88.3; 87.1…
Retinopathy of Prematurity
Primary: Number of Participants With Successful Treatment of ROP — 11; 14; 21; 9 Participants
COVID-19 · Coronavirus · SARS-CoV-2
Primary: COVID-19 7-point Ordinal Clinical Progression Outcomes Scale Score — 150; 144; 157; 167 Participants
Ulcerative Colitis
Primary: Clinical Remission — 30.3; 31.8; 22.7 percentage of participants
Colorectal Disease
Primary: Postoperative Pain as Measured by Pain Score — 2.60; 3.46 score on a scale
Major Depressive Disorder
Primary: Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Scores — 11; 12 score on a scale — p=0.58
Secondarily Infected Traumatic Skin Lesions
Primary: Proportion of Subjects in Each Treatment Group With Clinical Cure (Defined as a Skin Infection Rating Scale (SIRS) Score of 0 for All Signs and Symptoms) — 145; 169; 124…
Non-Alcoholic Steatohepatitis (NASH)
Primary: Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis) — 21…